Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Reduction of Coronavirus Burden With Mass Azithromycin Distribution.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02047981 (Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Secondary Effects from Mass Azithromycin Administration: A Systematic Review and Meta-analysis.The American journal of tropical medicine and hygiene · 2022Pooled it
- A bioinformatic analysis to systematically unveil shared pathways and molecular mechanisms underlying monkeypox and its predominant neurological manifestations.Frontiers in cellular and infection microbiology · 2025Article
- Beneficial ex vivo immunomodulatory and clinical effects of clarithromycin in COVID-19.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2022Article
- A determination of pan-pathogen antimicrobials?Medicine in drug discovery · 2022Review
- Rays of immunity: Role of sunshine vitamin in management of COVID-19 infection and associated comorbidities.Clinical nutrition ESPEN · 2021Review
- COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact.The American journal of tropical medicine and hygiene · 2021Review
- Azithromycin in viral infections.Reviews in medical virology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
We evaluated the potential antiviral effects of azithromycin on the nasopharyngeal virome of Nigerien children who had received multiple rounds of mass drug administration. We found that the respiratory burden of non-severe acute respiratory syndrome coronaviruses was decreased with azithromycin distributions. Clinical Trials Registration. NCT02047981.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.